核糖核酸局部胸腔灌注治疗恶性胸水的临床观察

Clinical Observation on Treatment of Malignant Hydrothorax with Ribonucleic Acid Intrapleural Injection

目的:观察胸腔内注入核糖核酸(BP素)治疗恶性胸水的疗效及不良反应。方法:62例恶性胸水患者,随机分为两组。治疗组32例胸腔内注入BP素100mg,对照组30例胸腔内注入顺铂(DDP)60～80mg,两组进行对照。结果:治疗组总有效率90.6%,对照组总有效率60.0%,差异有显著性(P<0.01);KPS评分改善率治疗组和对照组分别为26例(81.3%)和15例(50.0%),差异有显著性(P<0.0.1),治疗组不良反应仅为一过性反热。对照组骨髓抑制,恶心呕吐反应明显,与治疗组比较差异有显著性(P<0.01)。结论:BP素治疗恶性胸水有效率高,副作用少,能改善生存质量,值得临床推广应用。

Objective: To evaluate the efficacy and safety in treatment of malignant hydrothorax with Ribonucleic Acid intrapleural injection. Methods: 62 patients of treatment group were divided into two groups. 32 patients of treatment group were treated with Ribonucleic Acid 100mg intrapleural injection. 30 patients of control group were treated with DDP 60～80mg intrapleural injection. After the analysis of date, comparing the efficacy and safety of the two groups. Results: The effective rate of treatment group was 90.6%. The control group was 60.0%. They had a very significant difference between the two groups (P<0.01), The cases of the clinical benefit response of KPS was 27(81.3%) in the treatment group and 16(50.0%) in the control group. They also had a very significant difference (P<0.01). The major toxicity included transient fever in the treatment group and bone marrow suppression, Nausea and vomiting in the control group. The difference was very significant too(P<0.01). Conclusions: Ribonucleic Acid has a higher effective rate and a less toxicity in treatment of malignant hydrothorax. The reticular pleural adhesion is uniform and extensive. Ribonucleic Acid can improve appetite and quality of life of patients. Is worth of clinical popularizing.